论文部分内容阅读
目的:对老年咳嗽变异性哮喘(CVA)患者采取孟鲁司特钠联合布地奈德雾化吸入治疗的效果进行评析。方法:选取2016年2月~2017年2月在我院诊治的84例CVA患者纳入此次研究中,通过数字表法随机分成探究组和对比组,各42例;两组均给予积极对症治疗,同时对比组进行布地奈德雾化吸入治疗,探究组在对比组基础上服用孟鲁司特钠,治疗4周后,对比两组临床疗效,并评测治疗前后肺功能有关指标的改善情况,掌握两组不良反应发生率。结果:探究组的治疗总有效率为95.3%,对比组为80.9%,存在显著差异,有统计意义(P<0.05);治疗后,两组患者的FVC、FEV1、FEV1/FVC及PEF等指标均有改善,但探究组的改善效果更优于对比组(P<0.05);两组在治疗中均未出现明显不良反应。结论:孟鲁司特钠联合布地奈德雾化吸入治疗老年CVA效果确切,安全性高,可有效改善患者肺功能,有着重要的临床意义。
Objective: To evaluate the effect of inhalation of montelukast combined with budesonide inhalation on senile cough variant asthma (CVA). Methods: Eighty-four patients with CVA diagnosed and treated in our hospital from February 2016 to February 2017 were enrolled in this study and were randomly divided into inquiry group and control group by digital table method, 42 cases in each group. Both groups were given positive symptomatic treatment , While the control group inhaled budesonide inhalation therapy, the study group taking montelukast sodium on the basis of the control group, after 4 weeks of treatment, the clinical efficacy of the two groups were compared, and to evaluate the improvement of lung function before and after treatment, Grasp the incidence of adverse reactions in both groups. Results: The total effective rate of the treatment group was 95.3% and that of the control group was 80.9%, there was significant difference (P <0.05). After treatment, the indexes of FVC, FEV1, FEV1 / FVC and PEF But the improvement effect of the study group was better than that of the control group (P <0.05). No obvious adverse reactions were found in the two groups during the treatment. Conclusion: Montelukast combined with budesonide inhalation for the treatment of senile CVA is effective, safe and effective in improving pulmonary function. It has important clinical significance.